HGH Fragment 176-191 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: HGH fragment and AOD identity

Metabolic Research peptide Lyophilized verified

Also known as: Fragment 176-191, HGH Frag 176-191

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

2 mg, 5 mg, 10 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA. Less stable than AOD-9604 - do not assume interchangeable handling.

Solubility

Sequence salt and formulation dependent

Catalog Description

HGH Fragment 176-191 is the natural (unmodified) C-terminal amino-acid sequence of human growth hormone, studied for lipolytic activity via beta-3 adrenergic receptor stimulation without the growth-promoting/IGF-1-elevating effects of full-length HGH. AOD-9604 (see that record) is a stabilized, tyrosine-substituted version of this same fragment developed specifically to improve stability for pharmaceutical development - the two are closely related but not identical compounds, and researchers should not treat them as interchangeable in dosing or stability assumptions.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Not established for the catalog identity; do not import AOD-9604 values without sequence confirmation

Onset

Not established

Administration Routes (Research)

Laboratory useSC use is unapproved community practice

Reported Research Effects

Lipolytic activity via beta-3 adrenergic receptor stimulation
No IGF-1-elevating or growth-promoting effects (unlike full-length HGH)

Reported Research Side Effects

Human safety is inadequately characterized
Immunogenicity and peptide-impurity risks
Serious adverse events have been reported with AOD-9604 although causality is unclear

Data source: FDA AOD-9604 scientific review and current compounding risk notice

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

No validated human protocol is established for an ambiguously labeled HGH Fragment 176-191 product [SC or laboratory use; Not established; Not established]Source: identity and evidence gap

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Products that do not disclose full sequence and salt form
Substitution with AOD-9604 data without identity confirmation

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Marketed HGH Fragment 176-191 is frequently conflated with AOD-9604. FDA defines AOD-9604 as a specific synthetic cyclic 16-amino-acid peptide derived from hGH 177-191 with an added N-terminal tyrosine. Five duplicate fat-loss schedules were removed.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

FDA AOD-9604 scientific review — U.S. Food and Drug Administration
https://www.fda.gov/media/183584/download

FDA compounding safety-risk list — U.S. Food and Drug Administration
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.